Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they can be broadly prescribed.
In August, Teva published the full results of the Azilect trial, which showed that the drug slowed the progress of Parkinson's disease.
Teva rose 0.2 percent on Nasdaq yesterday to $42.95. The share fell 0.1 percent by midday on the TASE to NIS 160.90.
To see more of the Globes or to subscribe to the newspaper, go to http://www.globes.co.il. Copyright (c) 2008, Globes, Tel Aviv, Israel Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index